Study on anaesthetic agent propofol and sevoflurane as maintenance agent along with anti-emetic drug ondansetron in reducing post operative nausea and vomiting in high-risk patients Authors: Lakshmi Sunil, Geetha Rajesh Acharya Published: 2026 ABSTRACT BackgroundPostoperative nausea and vomiting (PONV) remain among the most common and distressing complications following general anaesthesia, significantly affecting patient satisfaction, recovery times, and healthcare costs. Although ondansetron at a dose of 4 mg IV has long been considered the gold standard for PONV prophylaxis, emerging literature suggests that higher doses may improve efficacy in select high-risk populations. However, the relationship between ondansetron dose, anaesthetic regimen, and PONV incidence remains poorly defined, particularly when using a combination of propofol induction and sevoflurane maintenance.ObjectiveThis prospective observational study aimed to evaluate the incidence of early PONV (within the first two postoperative hours) following pre-induction administration of ondansetron 4 mg in patients receiving propofol–sevoflurane anaesthesia and to assess the influence of demographic and perioperative factors on emesis incidence.MethodsOne hundred fifty high-risk adult patients aged 18–60 years undergoing elective surgery under general anaesthesia were enrolled. All received ondansetron 4 mg IV during premedication, propofol for induction, and sevoflurane for maintenance. Episodes of nausea and vomiting were recorded at 30, 60, 90, and 120 min postoperatively. Statistical analyses included Mann–Whitney U tests for continuous variables and Fisher’s exact tests for categorical data, with significance set at p < 0.05.ResultsA total of 150 patients were included in the analysis. The mean age of the cohort was 39.9 ± 13.1 years, with a predominance of female patients (63.3%). The overall incidence of early postoperative nausea and vomiting (within 120 min) was 9.3% (14/150). Most episodes were mild in severity, with only a small proportion of patients experiencing repeated vomiting.No statistically significant associations were identified between PONV and demographic variables such as age, sex, body mass index, smoking status, or prior history of PONV (p > 0.05). However, a higher proportion of PONV was observed among patients undergoing otorhinolaryngological procedures, although this did not reach statistical significance when analysed across all surgical departments.ConclusionOndansetron 4 mg IV administered pre-medication, combined with propofol induction and sevoflurane maintenance, effectively reduced early PONV incidence to 9.3% among high-risk adults. A higher incidence of PONV was observed in patients undergoing ENT procedures. These findings support the continued use of 4 mg as a sufficient and safe prophylactic dose for early postoperative periods, while underscoring the need for larger comparative studies evaluating dose-response relationships and late PONV outcomes. Introduction Postoperative nausea and vomiting (PONV) are among the most common adverse effects of anaesthesia, with a reported incidence of 20% to 30% in the general surgical population and up to 80% in high-risk groups such as females, nonsmokers, and those with a history of motion sickness or prior PONV [1–3]. Although not life-threatening, PONV causes considerable discomfort, delays discharge, increases unplanned admissions, and decreases overall patient satisfaction with anaesthesia [3]. Uncontrolled PONV can lead to wound dehiscence, aspiration pneumonia, electrolyte disturbances, dehydration, and significantly increased healthcare costs [4]. In ambulatory settings, PONV can compromise fast-track recovery goals and increase economic burdens through extended postoperative care and medication use [5, 6]. The multifactorial aetiology of PONV involves an interplay among patient characteristics, surgical procedures, and anaesthetic techniques [6]. Serotonin release from enterochromaffin cells during surgery plays a pivotal role in activating vagal afferents via 5-Hydroxytryptamine-3 5-H(T₃) receptors, triggering emetic pathways in the brainstem [7, 8]. This understanding led to the development of 5-HT₃ receptor antagonists such as ondansetron, which revolutionised PONV management upon their introduction in the early 1990s [9]. Ondansetron remains the cornerstone of antiemetic prophylaxis due to its rapid onset, minimal sedation, and favourable side effect profile [10]. The commonly recommended intravenous dose is 4 mg, a value historically established from early dose-ranging studies [11]. However, emerging evidence suggests that this standard dose may not be universally optimal. A meta-analysis by Apfel et al. (2020) suggested that higher doses (6–8 mg) could improve PONV prevention in high-risk or obese populations, though at the cost of a marginally increased risk of QT interval prolongation [11]. Other studies have found no significant difference between 4 mg and higher doses, raising questions about whether the “one-size-fits-all” strategy remains justified in modern anaesthesia [12, 13]. At the same time, the anaesthetic regimen itself significantly influences PONV risk [13]. Propofol, widely used for induction and maintenance, possesses intrinsic antiemetic properties. Several randomised trials have demonstrated that total intravenous anaesthesia (TIVA) with propofol reduces PONV incidence compared with volatile anaesthetics like sevoflurane or desflurane [14]. However, in practical clinical settings, many anaesthesiologists use propofol for induction followed by sevoflurane for maintenance to balance hemodynamic stability, cost, and recovery profile. This combination’s interaction with ondansetron efficacy remains underexplored, especially in diverse, high-risk populations [15]. Previous literature predominantly focused on homogenous populations, particularly female patients undergoing laparoscopic procedures [16, 17]. Moreover, most studies examined 24-hour PONV incidence rather than early postoperative outcomes, despite evidence suggesting that nearly half of PONV events occur within the first two hours [2, 18, 19]. Early prophylaxis is critical, as untreated emesis during recovery can lead to aspiration, wound dehiscence, or increased intracranial pressure in neurosurgical cases. Limited real-world data are evaluating the effectiveness of standard-dose (4 mg) ondansetron in preventing early PONV when combined with propofol induction and sevoflurane maintenance, particularly in high-risk mixed-gender populations. Understanding whether this regimen provides sufficient early protection—or whether higher doses or combination therapy are warranted—could directly inform anaesthesia protocols and improve patient outcomes. The present prospective observational study was designed to address this gap by evaluating early (0–120 min) PONV incidence following administration of ondansetron 4 mg IV in high-risk adult patients receiving propofol–sevoflurane anaesthesia. Materials and methods Study design and setting This was a prospective observational study conducted in the tertiary centre. The study was designed to evaluate the effectiveness of a single standard dose of ondansetron (4 mg IV) for the prevention of early postoperative nausea and vomiting in high-risk adults undergoing surgery under general anaesthesia with propofol induction and sevoflurane maintenance. The study included patients undergoing a heterogeneous range of surgical procedures, including laparoscopic abdominal surgeries (laparoscopic cholecystectomy, appendectomy, hernioplasty), gynaecological procedures (TAH, TLH, myomectomy, ovarian cystectomy), breast surgeries (MRM, lumpectomy), ENT/head–neck surgeries (septoplasty, tympanoplasty, thyroidectomy, FESS, commando procedures), urological procedures (PCNL, nephrectomy, cystoscopy), and neurosurgical procedures. The study followed the ethical principles of the Declaration of Helsinki (2013) and was approved by the Institutional Ethics Committee [20]. Written informed consent was obtained from all participants. Participants Adult patients between 18 and 60 years of age, classified as high risk for PONV based on the modified Apfel scoring system, were included. High-risk criteria included female sex, non-smoking status, history of motion sickness or previous PONV, and anticipated use of volatile anaesthetics or opioids. Exclusion criteria included pregnancy, significant hepatic or renal dysfunction, chronic antiemetic therapy, known ondansetron allergy, QT prolongation, and emergency surgeries. Anaesthetic technique All patients underwent preoperative evaluation, including fasting verification, airway assessment, and baseline vital parameters. Standard intraoperative monitoring (ECG, pulse oximetry, non-invasive blood pressure, end-tidal CO₂, and temperature) was employed. Premedication included glycopyrrolate 0.2 mg and midazolam 1 mg intravenously. Each patient received ondansetron 4 mg IV as prophylaxis five minutes before induction. Intravenous fentanyl 100 µg was administered perioperatively as part of the standard analgesic protocol. Anaesthesia induction was achieved with propofol 1–2 mg/kg, followed by neuromuscular blockade using vecuronium or rocuronium as per the anaesthesiologist’s preference. Anaesthesia was maintained with sevoflurane (1–2%) in a 50:50 air–oxygen mixture. Postoperative pain management was provided using a multimodal analgesic approach, including paracetamol and regional nerve blocks where indicated. Controlled ventilation was adjusted to maintain normocapnia. At the end of surgery, sevoflurane was discontinued, and residual neuromuscular blockade was reversed with 0.05 mg neostigmine and 8ug/kg glycopyrrolate. Postoperative assessment and data collection Postoperatively, patients were monitored in the post-anaesthesia care unit (PACU) for two hours. The primary outcome – PONV - was recorded at 30, 60, 90, and 120 min after extubating the patient. Emesis events (including nausea, retching, or vomiting) were recorded by trained nursing staff using a standardised emesis score (0 = none, 1 = nausea, 2 = vomiting once, 3 = recurrent vomiting) [18]. For analysis, any emesis score > 0 during the 120 min was classified accordingly. Demographic and perioperative data, including age, sex, BMI, type and duration of surgery, smoking history, previous PONV history, and intraoperative drugs, were recorded. Statistical analysis Data were analysed using Python (v3.11; Pandas, SciPy). Descriptive statistics summarised continuous variables as mean ± SD or median (IQR) and categorical variables as frequencies (%). The Mann–Whitney U test compared continuous variables between patients with and without PONV, given the small event count and non-normal distribution. Fisher’s exact test or chi-square test was used for categorical comparisons. Significance was defined as p < 0.05. Results Demographic characteristics One hundred fifty patients were included in the final analysis after excluding incomplete records. The cohort consisted of 95 females (63.3%) and 55 males (36.7%), with a mean age of 39.9 ± 13.1 years (range 18–60 years). The mean BMI was 24.2 ± 4.4 kg/m². A total of 53 patients (35.3%) were smokers, while only 9 (6.0%) had a history of PONV, as shown in Table 1. All patients received ondansetron 4 mg IV pre-induction, and anaesthesia was induced with propofol followed by sevoflurane maintenance. Rescue antiemetics and patient satisfaction scores (1–5 scale) were also noted. Table 1Baseline demographic and clinical characteristics (N = 150)VariableMean ± SD or n (%)Age (years)39.9 ± 13.1SexFemale: 95 (63.3%)Male: 55 (36.7%)BMI (kg/m²)24.2 ± 4.4History of PONVYes: 9 (6.0%)No: 141 (94.0%)Smoking HistoryYes: 53 (35.3%)No: 97 (64.7%)Ondansetron Dose4 mg (100%) Table 1Baseline demographic and clinical characteristics (N = 150)VariableMean ± SD or n (%)Age (years)39.9 ± 13.1SexFemale: 95 (63.3%)Male: 55 (36.7%)BMI (kg/m²)24.2 ± 4.4History of PONVYes: 9 (6.0%)No: 141 (94.0%)Smoking HistoryYes: 53 (35.3%)No: 97 (64.7%)Ondansetron Dose4 mg (100%) Baseline demographic and clinical characteristics (N = 150) Incidence of early PONV Only fourteen patients (9.3%) experienced nausea or vomiting within the first 120 min postoperatively, as shown in Table 2. No significant hemodynamic instability or adverse events related to ondansetron administration were reported. Table 2Incidence and severity of early PONV within 120 min post operativelyPONV ScoreDescription n %0No nausea/vomiting13690.7%1Nausea only64.0%2Nausea + vomiting53.3%≥ 3Repeated vomiting32.0% Table 2Incidence and severity of early PONV within 120 min post operativelyPONV ScoreDescription n %0No nausea/vomiting13690.7%1Nausea only64.0%2Nausea + vomiting53.3%≥ 3Repeated vomiting32.0% Incidence and severity of early PONV within 120 min post operatively Table 3High risk factors of PONV within 120 min post operativelyVariableNo PONVPONVTest Usedp-valueAge (years, median [IQR])38 [30–48]46 [35–55]Mann–Whitney U0.11BMI (kg/m², median [IQR])24.1 [21.5–27.0]24.6 [22.0–27.5]Mann–Whitney U0.81Female sex (%)85 (62.5%)11 (78.6%)Fisher’s exact0.29History of PONV (%)8 (5.9%)1 (7.1%)Fisher’s exact1.00Smoking (%)48 (35.3%)5 (35.7%)Fisher’s exact1.00 Table 3High risk factors of PONV within 120 min post operativelyVariableNo PONVPONVTest Usedp-valueAge (years, median [IQR])38 [30–48]46 [35–55]Mann–Whitney U0.11BMI (kg/m², median [IQR])24.1 [21.5–27.0]24.6 [22.0–27.5]Mann–Whitney U0.81Female sex (%)85 (62.5%)11 (78.6%)Fisher’s exact0.29History of PONV (%)8 (5.9%)1 (7.1%)Fisher’s exact1.00Smoking (%)48 (35.3%)5 (35.7%)Fisher’s exact1.00 High risk factors of PONV within 120 min post operatively Median age was higher among those who developed PONV (46 years) than those who did not (38 years), though this difference was not statistically significant (p = 0.11). There were no significant associations between PONV and BMI (p = 0.81), sex (p = 0.29), smoking (p = 1.00) or history of prior PONV (p = 1.000), as shown in Table 3. Overall, while certain trends such as female predominance were noted, none of the evaluated factors emerged as significant predictors in this study. Department-wise analysis While department-wise comparison did not reach statistical significance, likely due to unequal group sizes and limited event rates, revealed a significantly higher incidence of PONV in ENT procedures (16.7%) (As shown in Table 4). Table 4Department-wise distribution of surgical procedures and incidence of PONV (N = 150)DepartmentCommon Surgical ProceduresTotal (n)No PONV (n, %)PONV (n, %)ENT / Head–Neck SurgerySeptoplasty, tympanoplasty, thyroidectomy, FESS, commando procedures4235 (83.3%)7 (16.7%)General SurgeryLaparoscopic cholecystectomy, appendectomy, hernioplasty3835 (92.1%)3 (7.9%)GynaecologyTAH, TLH, myomectomy, ovarian cystectomy3028 (93.3%)2 (6.7%)OrthopaedicsArthroscopy, fracture fixation, joint procedures2523 (92.0%)2 (8.0%)OthersUrological and neurosurgical procedures1515 (100%)0 (0%)Total150136 (90.7%)14 (9.3%) Table 4Department-wise distribution of surgical procedures and incidence of PONV (N = 150)DepartmentCommon Surgical ProceduresTotal (n)No PONV (n, %)PONV (n, %)ENT / Head–Neck SurgerySeptoplasty, tympanoplasty, thyroidectomy, FESS, commando procedures4235 (83.3%)7 (16.7%)General SurgeryLaparoscopic cholecystectomy, appendectomy, hernioplasty3835 (92.1%)3 (7.9%)GynaecologyTAH, TLH, myomectomy, ovarian cystectomy3028 (93.3%)2 (6.7%)OrthopaedicsArthroscopy, fracture fixation, joint procedures2523 (92.0%)2 (8.0%)OthersUrological and neurosurgical procedures1515 (100%)0 (0%)Total150136 (90.7%)14 (9.3%) Department-wise distribution of surgical procedures and incidence of PONV (N = 150) Rescue antiemetic use and patient satisfaction Among the 14 patients who developed PONV, 8 required rescue antiemetic therapy, for which an additional dose of ondansetron 4 mg IV was administered. The overall mean satisfaction score was 4.7 ± 0.4 (see Table 5), indicating high postoperative comfort. No significant correlation was found between satisfaction score and age, sex, or BMI. Table 5Patient Satisfaction ScoresParameterValuePatient Satisfaction Score (1–5)4.7 ± 0.4Satisfaction DistributionVery satisfied (5): 118 (78.7%)Satisfied (4): 27 (18.0%)Neutral (3): 5 (3.3%)Dissatisfied (1–2): 0 (0%) Table 5Patient Satisfaction ScoresParameterValuePatient Satisfaction Score (1–5)4.7 ± 0.4Satisfaction DistributionVery satisfied (5): 118 (78.7%)Satisfied (4): 27 (18.0%)Neutral (3): 5 (3.3%)Dissatisfied (1–2): 0 (0%) Patient Satisfaction Scores Discussion Postoperative nausea and vomiting remain a persistent challenge in anaesthesia despite advances in pharmacology and monitoring. The current study contributes valuable real-world data supporting the adequacy of the standard ondansetron 4 mg dose when combined with propofol induction and sevoflurane maintenance in high-risk adults. Clinical significance of the 4 mg dose Ondansetron at 4 mg IV remains the globally accepted standard for PONV prophylaxis, offering a balance between efficacy, safety, and cost-effectiveness. Its pharmacokinetic profile provides a therapeutic plasma concentration for 4–6 h, corresponding well with the early postoperative phase when emesis risk peaks [18]. The very low incidence of early PONV (9.3%) in this study confirms that the 4 mg dose remains clinically sufficient, particularly when paired with propofol’s intrinsic antiemetic effects. In contrast, several studies have questioned whether higher doses might offer additional benefit. A 2021 randomised controlled trial by Akhavan et al. found no significant reduction in PONV incidence between 4 mg and 8 mg doses but reported a higher frequency of mild headache and QTc prolongation in the 8 mg group [21]. Similarly, a meta-analysis by Zhang et al. (2023) showed that while 8 mg may slightly reduce late-onset (6–24 h) PONV, the improvement was not clinically meaningful in low- to moderate-risk groups [22]. Thus, escalating the ondansetron dose beyond 4 mg may not yield proportional benefit and could increase cost and safety concerns. Anaesthetic technique and its influence on PONV Anaesthetic technique plays a pivotal role in modulating PONV risk. Propofol, used for induction in all patients, is known to reduce PONV incidence through its action on GABAergic and serotonergic pathways [23]. Sevoflurane, while generally considered emetogenic, was used at low dial concentrations (1–2%), minimising its potential to trigger nausea. The synergistic effect of low-dose sevoflurane and propofol may therefore explain the extremely low PONV incidence in this cohort. Our findings align with a 2019 clinical report by Uchinami et al., who found no significant difference in PONV incidence when low-concentration sevoflurane was combined with propofol compared to propofol-only anaesthesia [24]. Likewise, Bansal et al. reported that propofol–sevoflurane combinations achieved comparable outcomes to total intravenous anaesthesia in female laparoscopic patients when paired with 5-HT₃ antagonists [15]. Neuromuscular blockade reversal with neostigmine was performed according to standard institutional practice and may have contributed to PONV because cholinergic effects of neostigmine have been associated with increased nausea and vomiting in some patients [25, 26]. In addition, intermittent opioid supplementation was administered for perioperative analgesia, which could also have affected PONV incidence, as opioids are recognised risk factors for postoperative emesis [27]. These perioperative variables should therefore be considered while interpreting the study findings. Current evidence supports the use of opioid-sparing anaesthetic techniques and multimodal antiemetic strategies to reduce PONV risk [28]. Measures such as minimising perioperative opioid use, adequate hydration, use of combination antiemetic prophylaxis, and individualised risk-based prevention approaches may improve postoperative outcomes [28]. Additional perioperative measures may also contribute to reducing PONV risk. Nitrous oxide was avoided in high-risk patients, as it has been associated with increased postoperative nausea and vomiting in previous studies [29]. Other perioperative measures including, minimising exposure to volatile anaesthetic agents where feasible and encouraging early postoperative mobilisation, may also help reduce PONV incidence [30]. In addition to pharmacological prophylaxis, anaesthetic techniques also play an important role in reducing PONV risk. Avoiding excessive insufflation of the upper gastrointestinal tract during face mask ventilation may help decrease gastric distension and thereby reduce postoperative nausea and vomiting. Comparative analysis with prior studies The observed 9.3% incidence is substantially lower than that reported in prior literature, where early postoperative PONV rates of 10–30% are common despite prophylaxis [15]. The difference may be attributed to the uniform administration of ondansetron before induction and the dual anaesthetic strategy used. Importantly, this study highlights that even among high-risk patients, a standardised 4 mg ondansetron dose can provide reliable early prophylaxis when anaesthetic regimens are carefully optimised. Mechanistic insights The pharmacodynamic ceiling effect of ondansetron may explain the observed dose sufficiency. Beyond 4 mg, receptor saturation at the chemoreceptor trigger zone results in minimal incremental antiemetic benefit [31]. Additionally, propofol’s modulation of subcortical pathways, including dopaminergic inhibition, further enhances antiemetic synergy [32]. The combination effectively suppresses both central and peripheral emetic triggers, explaining the observed efficacy. Additional insights A particularly noteworthy finding was the higher occurrence of PONV among patients undergoing ENT procedures. Even without formal subgroup stratification, this trend was clearly evident and carries significant clinical relevance. The increased susceptibility in this group can be attributed to factors such as vestibular stimulation during middle ear manipulation, pharyngeal irritation, and blood ingestion, all of which are known to activate emetic pathways [33]. Although the department-wise association between surgical category and PONV did not achieve statistical significance (Chi-square test with Fisher’s correction, p = 0.072), a higher numerical incidence was observed among ENT/head–neck procedures. This trend may warrant further evaluation in larger, adequately powered studies before definitive recommendations regarding multimodal prophylaxis can be made. Interestingly, the incidence of PONV remained relatively low despite routine reversal with neostigmine as part of the institutional anaesthetic protocol. Neostigmine has previously been associated with greater emetogenic potential compared with Sugammadex in some studies [34]. Overall, the findings suggest that while ondansetron 4 mg prophylaxis was associated with a relatively low overall incidence of early PONV, certain surgical subgroups may continue to demonstrate increased susceptibility despite standard prophylaxis. Further prospective comparative studies are needed before definitive recommendations regarding tailored or multimodal antiemetic strategies can be established. Implications for practice These findings reinforce that the standard ondansetron 4 mg dose remains adequate for early postoperative prophylaxis, even in high-risk individuals. This has practical implications for anaesthesia providers globally, particularly in resource-limited settings were escalating doses or combining multiple antiemetics increases cost without proportionate benefit. Moreover, the low event rate reduces the need for polypharmacy, aligning with enhanced recovery after surgery (ERAS) principles emphasising streamlined, evidence-based interventions. Overall, this study reinforces the importance of risk stratification in PONV prevention, highlighting that even within a generally low-incidence cohort, specific subgroups continue to demonstrate increased vulnerability. Limitations The study’s limitations include its single-centre design and short (120-minute) observation period. Late PONV, which may occur up to 24 h postoperatively, was not evaluated. Additionally, as all patients received the same ondansetron dose, a true dose–response analysis could not be performed. Future multicentre randomised controlled trials comparing 4 mg versus 8 mg ondansetron under similar anaesthetic conditions would provide more definitive evidence. Although perioperative variables such as duration of surgery and intraoperative opioid administration were documented clinically, the observational design and limited number of PONV events did not permit meaningful subgroup analysis of these factors. Furthermore, while a higher occurrence of PONV was observed in patients undergoing ENT procedures, detailed subgroup analysis was limited and requires further validation in larger studies. Conclusion In this prospective observational study, Ondansetron 4 mg IV was associated with a relatively low incidence of early PONV in this cohort and appears to be an effective prophylactic option in routine clinical practice. The observed incidence of only 9.3% supports the adequacy of the standard dose for early PONV prophylaxis. The combination of a propofol-based induction with low-dose sevoflurane maintenance may provide additive protection against PONV. Given its safety, cost-effectiveness, and consistent clinical performance, ondansetron 4 mg remains the optimal choice for early postoperative prophylaxis in high-risk patients. However, future studies comparing dose escalation, combination regimens, and late PONV outcomes are warranted to refine antiemetic protocols for diverse patient populations. Although ENT procedures demonstrated a higher numerical incidence of PONV, larger controlled studies are required before definitive preventive recommendations can be established for this subgroup.